ApprovedFDA approval

Zanvastro (zilganersen)

Ionis Pharmaceuticals (IONS)

Marketer take

Alexander disease had no FDA-approved disease-specific therapy, so this is a category-creating rare neurology launch built on genetic diagnosis, leukodystrophy centers and advocacy groups.

Sponsor company
Ionis Pharmaceuticals (IONS)
Indication
To treat Alexander disease in pediatric and adult patients
Therapeutic area
Neurology, Rare disease
Event
FDA approval
Date
Sep 3, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move